Opioid Sparing Outcomes, Non-Opioid Alternatives To Get Spotlight From US FDA Advisory Cmte.

While appropriate prescribing practices have grabbed a bulk of the spotlight in the US FDA's strategy to combat the opioid crisis, the agency is gearing up for a deeper dive into another facet of its approach: the development of opioid-sparing regimes and non-opioid pain medications.

FDA will convene its Anesthetic and Analgesic Drug Products Advisory Committee Nov. 15 to discuss a broad range of questions on the topic, including how to define a clinically meaningful decrease in opioid use to support an opioid-sparing claim and the pros and cons of various study designs